Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

ZG005 20mg/kg, intravenous infusion(IV), once every 3 weeks (Q3W)

Part 1: Cohort A：Gecacitinib is administered continuously until the end of treatment; Cohort B：Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21；Part 2：Gecacitinib for dose exploratory stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose escalation stage.

Bevacizumab 7.5 mg/kg，intravenous infusion(IV), once every 3 weeks (Q3W)